SE9002659D0 - New pharmaceutical formulations - Google Patents

New pharmaceutical formulations

Info

Publication number
SE9002659D0
SE9002659D0 SE9002659A SE9002659A SE9002659D0 SE 9002659 D0 SE9002659 D0 SE 9002659D0 SE 9002659 A SE9002659 A SE 9002659A SE 9002659 A SE9002659 A SE 9002659A SE 9002659 D0 SE9002659 D0 SE 9002659D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical formulations
new pharmaceutical
new
methylthiazole
solvate
Prior art date
Application number
SE9002659A
Other languages
English (en)
Swedish (sv)
Inventor
B R Boar
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9002659A priority Critical patent/SE9002659D0/xx
Publication of SE9002659D0 publication Critical patent/SE9002659D0/xx
Priority to HU9300388A priority patent/HUT65821A/hu
Priority to AU84092/91A priority patent/AU657490B2/en
Priority to CA002088775A priority patent/CA2088775A1/en
Priority to RO93-00194A priority patent/RO112994B1/ro
Priority to PCT/SE1991/000522 priority patent/WO1992003134A1/en
Priority to EP91915138A priority patent/EP0619734B1/en
Priority to ES91915138T priority patent/ES2114891T3/es
Priority to DE69129126T priority patent/DE69129126T2/de
Priority to JP03514007A priority patent/JP3094077B2/ja
Priority to CS93166A priority patent/CZ279586B6/cs
Priority to RU9193004984A priority patent/RU2093155C1/ru
Priority to DK91915138T priority patent/DK0619734T3/da
Priority to AT91915138T priority patent/ATE164066T1/de
Priority to SK8793A priority patent/SK8793A3/sk
Priority to NZ239329A priority patent/NZ239329A/en
Priority to IE281891A priority patent/IE912818A1/en
Priority to IL9916991A priority patent/IL99169A/en
Priority to US07/744,914 priority patent/US5385921A/en
Priority to IS3743A priority patent/IS3743A7/is
Priority to PT98688A priority patent/PT98688B/pt
Priority to NO930452A priority patent/NO303447B1/no
Priority to FI930608A priority patent/FI930608A0/fi
Priority to BG97446A priority patent/BG97446A/xx
Priority to LVP-93-1024A priority patent/LV10921B/en
Priority to LTIP1714A priority patent/LT3978B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9002659A 1990-08-15 1990-08-15 New pharmaceutical formulations SE9002659D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations
DE69129126T DE69129126T2 (de) 1990-08-15 1991-08-07 Neue pharmazeutische formulierungen von 5-(2-chlor-1-hydroxyethyl)-4-methylthiazol
DK91915138T DK0619734T3 (da) 1990-08-15 1991-08-07 Nye farmaceutiske formuleringer af 5-(2-chlor-1-hydroxyethyl)-4-methylthiazol
SK8793A SK8793A3 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chlor-1-hydroxyethyl)-4-methylthiazole
CA002088775A CA2088775A1 (en) 1990-08-15 1991-08-07 Pharmaceutical formulations of 5- (2-chloro-1-hydroxyethyl)-4-methylthiazole
RO93-00194A RO112994B1 (ro) 1990-08-15 1991-08-07 Metoda pentru prevenirea si tratarea degenerarilor neurologice
PCT/SE1991/000522 WO1992003134A1 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole
EP91915138A EP0619734B1 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole
ES91915138T ES2114891T3 (es) 1990-08-15 1991-08-07 Nuevas formulaciones farmaceuticas de 5-(2-cloro-1-hidroxietil)-4-metiltiazol.
AU84092/91A AU657490B2 (en) 1990-08-15 1991-08-07 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole
JP03514007A JP3094077B2 (ja) 1990-08-15 1991-08-07 ５−（２−クロロ−１−ヒドロキシエチル）−４−メチルチアゾール含有の医薬製剤
CS93166A CZ279586B6 (cs) 1990-08-15 1991-08-07 Nové farmaceutické prostředky z 5-(2-chlor-1-hydroxyethyl)-4-methylthiazolu
RU9193004984A RU2093155C1 (ru) 1990-08-15 1991-08-07 Применение 5-[2-хлор-1-гидроксиэтил]-4-метилтиазола для снижения поражения нейронов, подавления конвульсий и снижения двигательной активности
HU9300388A HUT65821A (en) 1990-08-15 1991-08-07 Process for preparing anti-neurodegenerative pharmaceutical preparations containing 5-(chloro-1-hydroxyethyl)-4-methylthiazole
AT91915138T ATE164066T1 (de) 1990-08-15 1991-08-07 Neue pharmazeutische formulierungen von 5-(2- chlor-1-hydroxyethyl)-4-methylthiazol
NZ239329A NZ239329A (en) 1990-08-15 1991-08-09 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole and its salts, pharmaceutical compositions thereof
IE281891A IE912818A1 (en) 1990-08-15 1991-08-09 New pharmaceutical formulations
IL9916991A IL99169A (en) 1990-08-15 1991-08-12 Medicinal products containing 4-methylthiazole
US07/744,914 US5385921A (en) 1990-08-15 1991-08-14 Pharmaceutical formulations
IS3743A IS3743A7 (is) 1990-08-15 1991-08-14 Ný notkun á 5-(2 klóró-1-hýdroxíetýl)-4-metýlþíasól
PT98688A PT98688B (pt) 1990-08-15 1991-08-14 Processo para a preparacao de composicoes farmaceuticas contendo 5-(2-cloro-1-hidroxietil)-4-metiltiazol
NO930452A NO303447B1 (no) 1990-08-15 1993-02-09 AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt hydrokloridsalt eller etandisulfonatsalt av 5-(2-klor-1-hydroksyetyl)-4-metyltiazol
FI930608A FI930608A0 (fi) 1990-08-15 1993-02-11 Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol
BG97446A BG97446A (en) 1990-08-15 1993-02-15 Pharmaceutical compositions of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole
LVP-93-1024A LV10921B (en) 1990-08-15 1993-08-10 Novel pharmaceutical formulations
LTIP1714A LT3978B (en) 1990-08-15 1993-12-30 New pharmaceutical formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SE9002659D0 true SE9002659D0 (sv) 1990-08-15

Family

ID=20380161

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations

Country Status (26)

Country Link
US (1) US5385921A (pt)
EP (1) EP0619734B1 (pt)
JP (1) JP3094077B2 (pt)
AT (1) ATE164066T1 (pt)
AU (1) AU657490B2 (pt)
BG (1) BG97446A (pt)
CA (1) CA2088775A1 (pt)
CZ (1) CZ279586B6 (pt)
DE (1) DE69129126T2 (pt)
DK (1) DK0619734T3 (pt)
ES (1) ES2114891T3 (pt)
FI (1) FI930608A0 (pt)
HU (1) HUT65821A (pt)
IE (1) IE912818A1 (pt)
IL (1) IL99169A (pt)
IS (1) IS3743A7 (pt)
LT (1) LT3978B (pt)
LV (1) LV10921B (pt)
NO (1) NO303447B1 (pt)
NZ (1) NZ239329A (pt)
PT (1) PT98688B (pt)
RO (1) RO112994B1 (pt)
RU (1) RU2093155C1 (pt)
SE (1) SE9002659D0 (pt)
SK (1) SK8793A3 (pt)
WO (1) WO1992003134A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901658D0 (sv) * 1999-05-06 1999-05-06 Astra Ab New formulation
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
US6699866B2 (en) 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
CN103772313B (zh) * 2014-01-02 2015-10-14 郑桂富 一种4-甲基-5-(2-羟乙基)噻唑的合成方法
CN112262814A (zh) * 2020-10-26 2021-01-26 宜宾学院 油樟叶渣发酵床养鸡方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825966A1 (de) * 1978-06-14 1980-01-03 Basf Ag Saures galvanisches nickelbad, das sulfobetaine als glanz- und einebnungsmittel enthaelt
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists

Also Published As

Publication number Publication date
DK0619734T3 (da) 1998-10-05
DE69129126T2 (de) 1998-07-23
FI930608A (fi) 1993-02-11
CA2088775A1 (en) 1992-02-16
LT3978B (en) 1996-06-25
JP3094077B2 (ja) 2000-10-03
ES2114891T3 (es) 1998-06-16
IS3743A7 (is) 1992-02-16
PT98688B (pt) 1999-01-29
US5385921A (en) 1995-01-31
HU9300388D0 (en) 1993-04-28
AU8409291A (en) 1992-03-17
SK8793A3 (en) 1993-07-07
CZ16693A3 (en) 1994-02-16
BG97446A (en) 1994-03-24
WO1992003134A1 (en) 1992-03-05
NZ239329A (en) 1994-11-25
PT98688A (pt) 1992-07-31
AU657490B2 (en) 1995-03-16
NO930452D0 (no) 1993-02-09
NO930452L (no) 1993-02-09
IE912818A1 (en) 1992-02-26
IL99169A0 (en) 1992-07-15
JPH06500097A (ja) 1994-01-06
DE69129126D1 (de) 1998-04-23
LV10921B (en) 1996-08-20
NO303447B1 (no) 1998-07-13
IL99169A (en) 1995-10-31
CZ279586B6 (cs) 1995-05-17
EP0619734A1 (en) 1994-10-19
LTIP1714A (en) 1995-09-25
LV10921A (lv) 1995-12-20
EP0619734B1 (en) 1998-03-18
ATE164066T1 (de) 1998-04-15
HUT65821A (en) 1994-07-28
FI930608A0 (fi) 1993-02-11
RU2093155C1 (ru) 1997-10-20
RO112994B1 (ro) 1998-03-30

Similar Documents

Publication Publication Date Title
FI933248A (fi) Optiskt aktiva 5h-pyrrolo(3,4-b)pyrazinderat, dess framstaellning och farmaceutiska kompositioner innehaollande detta
FI915826A (fi) Farmaceutiska aemnen.
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
DK0535034T3 (da) Farmaceutisk aktive benzoquinazolinforbindelser
NO180445C (no) 2-(4-hydroksypiperidino)-1-alkanol-derivater som anti-iskemiske midler
SE9002659D0 (sv) New pharmaceutical formulations
FI882965A (fi) Aminocyklopentyletrar och deras framstaellning och farmaceutiska preparat.
FI923371A0 (fi) En farmaceutisk formulation.
DE69013131D1 (de) 2-(2-Cyclopropylpyrrolidin-4-ylthio)carbapenemderivate.
NO306381B1 (no) Farmasöytisk ampulle
RU93004984A (ru) Фармацевтическая композиция на основе 5(2-хлор-1-гидроксиэтил)-4-метилтиазола, применение 5-(2-хлор-1-гидроксиэтил)-4-метил-тиазола для лечения, способ лечения, соли 5-(2-хлор-1-гидроксиэтил)-4-метилтиазола
SE9000948D0 (sv) New use
NO912979L (no) Fremgangsmaate for fremstilling av 2-(9-fluorenoyl)-carbapenederivater.
FI930967A0 (fi) Substituerade 6,7-dihydroimidazo(1,5,4-ef)(1,5)bensodiazepin-6-oner, deras framstaellning och farmaceutiska kompositioner
SE9000288D0 (sv) New use
ITMI911049A0 (it) Composizione oftalmica
MX9203359A (es) Nuevas composiciones farmaceuticas de insulina.
MX9202442A (es) Derivados de azol.
FI971316A0 (fi) Farmaseuttinen yhdiste
NO903685D0 (no) Dobbeltmuffe.
ITRM910200A0 (it) Procedimento per la produzione di lenti oftalmiche a contatto.